BTIG reinitiated its coverage of Orthofix Medical (NASDAQ:OFIX) with a “buy” rating and $27 price target. The stock closed at $20.65 on July 18. BTIG previously covered the legacy Orthofix from 2017-to-2021 and the...
Stifel launched coverage of Orthofix Medical (NASDAQ:OFIX) with a “buy” rating and price target of $39. The stock closed at $34.05 on Oct. 19. Orthofix is focused on providing medical devices, operating through the...
Orthofix Medical (NASDAQ:OFIX) received FDA clearance for its FIREBIRD SI fusion system and has treated its first patients for low back pain. The system is designed to compress and stabilize the sacroiliac (SI) joint...
Jon Serbousek Orthofix Medical (NASDAQ:OFIX) appointed Jon Serbousek as president, CEO and a director of its board, effective immediately. Mr. Serbousek succeeds Brad Mason, who previously announced his retirement. Mr...